MONTREAL, QUEBEC--(Marketwire - September 15, 2008) - Thallion Pharmaceuticals Inc. (TSX: TLN) announced today that it presented a scientific poster on its Phase II renal cell carcinoma clinical trial of TLN-232 at the 33rd European Society for Medical Oncology (ESMO) Congress held September 12-16, 2008 in Stockholm, Sweden.
